Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y.

Curr Med Res Opin. 2013 Feb;29(2):117-25. doi: 10.1185/03007995.2012.756393. Epub 2012 Dec 26. Review.

PMID:
23216340
2.
3.

Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.

Qi WX, Shen Z, Yao Y.

Cancer Chemother Pharmacol. 2012 Jan;69(1):99-106. doi: 10.1007/s00280-011-1678-9. Epub 2011 May 24.

PMID:
21607554
4.
5.

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.

Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO).

J Cancer Res Clin Oncol. 2012 Feb;138(2):221-9. doi: 10.1007/s00432-011-1091-0. Epub 2011 Nov 18. Review.

6.

Taxane-containing regimens for metastatic breast cancer.

Ghersi D, Willson ML, Chan MM, Simes J, Donoghue E, Wilcken N.

Cochrane Database Syst Rev. 2015 Jun 10;(6):CD003366. doi: 10.1002/14651858.CD003366.pub3. Review.

PMID:
26058962
7.

Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.

Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.

Health Technol Assess. 2007 Oct;11(40):1-144. Review.

8.

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.

Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C, Polyzos NP.

Cancer Treat Rev. 2010 Feb;36(1):69-74. doi: 10.1016/j.ctrv.2009.10.006. Epub 2009 Nov 27. Review.

PMID:
19945225
9.

A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.

Palmieri C, Alifrangis C, Shipway D, Tat T, Watson V, Mackie D, Emson M, Coombes RC.

Oncologist. 2012;17(11):1429-e47. doi: 10.1634/theoncologist.2012-0161. Epub 2012 Sep 21.

10.

Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials.

Zheng R, Han S, Duan C, Chen K, You Z, Jia J, Lin S, Liang L, Liu A, Long H, Wang S.

Medicine (Baltimore). 2015 May;94(17):e803. doi: 10.1097/MD.0000000000000803.

11.

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P.

J Clin Oncol. 2009 Aug 1;27(22):3611-9. doi: 10.1200/JCO.2008.18.5397. Epub 2009 May 26. Erratum in: J Clin Oncol. 2011 Jul 1;29(19):2739.

PMID:
19470941
12.

Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.

Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains JP, Paridaens R.

Crit Rev Oncol Hematol. 2010 Jul;75(1):70-7. doi: 10.1016/j.critrevonc.2009.07.001. Epub 2009 Aug 3.

PMID:
19651523
13.

Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

Jiang J, Huang L, Liang X, Zhou X, Huang R, Chu Z, Zhan Q.

Acta Oncol. 2011 May;50(4):582-8. doi: 10.3109/0284186X.2010.546368. Epub 2010 Dec 30.

PMID:
21190510
14.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
15.

Taxanes for adjuvant treatment of early breast cancer.

Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004421. Review.

PMID:
17943815
16.

A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.

Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J.

Lung Cancer. 2012 Jun;76(3):380-6. doi: 10.1016/j.lungcan.2011.12.001. Epub 2012 Jan 9.

PMID:
22226626
17.

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.

Dranitsaris G, Cottrell W, Spirovski B, Hopkins S.

J Oncol Pharm Pract. 2009 Jun;15(2):67-78. doi: 10.1177/1078155208098584. Epub 2008 Nov 26.

PMID:
19036903
18.

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.

Li X, Wang H, Lin W, Xu Q.

Curr Med Res Opin. 2014 Nov;30(11):2295-304. doi: 10.1185/03007995.2014.909392. Epub 2014 Apr 30. Review.

PMID:
24701984
19.

The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review.

Jassem J, Carroll C, Ward SE, Simpson E, Hind D.

Eur J Cancer. 2009 Nov;45(16):2749-58. doi: 10.1016/j.ejca.2009.05.035. Epub 2009 Jul 15. Review.

PMID:
19615886
20.

Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.

Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F, Giannarelli D.

Cancer Treat Rev. 2006 Dec;32(8):583-7. Epub 2006 Aug 21.

PMID:
16919884

Supplemental Content

Support Center